Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 478 Shares

Key Points

• Natera CFO Michael Burkes Brophy sold 478 shares at an average price of $274.22, generating $131,077.16. The Rule 10b5-1 transaction covered tax withholding tied to vested equity awards, reducing his position by 0.92% while leaving him with 51,637 shares.
• Brophy also sold shares in four recent transactions from July 27 through August 3, bringing his reported recent sales to several thousand shares.
• Natera shares recently traded at $274.58, near their 52-week high of $288.04. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $267.83, while institutional investors own 99.9% of the stock.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 478 shares of the firm's stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total value of $131,077.16. Following the sale, the chief financial officer owned 51,637 shares in the company, valued at $14,159,898.14. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, August 3rd, Michael Burkes Brophy sold 317 shares of Natera stock. The shares were sold at an average price of $267.99, for a total value of $84,952.83.
• On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The stock was sold at an average price of $249.38, for a total value of $464,594.94.
• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The stock was sold at an average price of $253.96, for a total value of $614,329.24.
• On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $203,703.18.

Natera Trading Down 0.2%

Shares of NASDAQ NTRA traded down $0.61 on Wednesday, reaching $274.58. 1,128,660 shares of the company traded hands, compared to its average volume of 1,104,859. Natera, Inc. has a fifty-two week low of $135.75 and a fifty-two week high of $288.04. The company has a 50 day moving average of $251.03 and a 200 day moving average of $222.85. The stock has a market capitalization of $39.32 billion, a PE ratio of -168.45 and a beta of 1.51.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its position in Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after buying an additional 1,225,420 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. State Street Corp boosted its position in Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock worth $545,624,000 after purchasing an additional 72,087 shares during the period. Coatue Management LLC boosted its position in Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Natera by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company's stock valued at $596,078,000 after purchasing an additional 11,689 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research analyst reports. Barclays dropped their price target on shares of Natera from $280.00 to $260.00 and set an "overweight" rating for the company in a research report on Wednesday, June 24th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $260.00 to $265.00 and gave the company an "overweight" rating in a research note on Friday, May 8th. BTIG Research set a $275.00 price objective on Natera and gave the stock a "buy" rating in a report on Wednesday, June 24th. Wall Street Zen lowered Natera from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. Finally, Robert W. Baird set a $265.00 target price on Natera in a report on Friday, May 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source